Key Insights

Highlights

Success Rate

94% trial completion (above average)

Published Results

315 trials with published results (34%)

Research Maturity

755 completed trials (80% of total)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 17/100

Termination Rate

5.2%

49 terminated out of 938 trials

Success Rate

93.9%

+7.4% vs benchmark

Late-Stage Pipeline

29%

271 trials in Phase 3/4

Results Transparency

42%

315 of 755 completed with results

Key Signals

315 with results94% success49 terminated

Data Visualizations

Phase Distribution

694Total
Not Applicable (201)
Early P 1 (4)
P 1 (100)
P 2 (118)
P 3 (165)
P 4 (106)

Trial Status

Completed755
Unknown74
Terminated49
Recruiting21
Withdrawn20
Active Not Recruiting9

Trial Success Rate

93.9%

Benchmark: 86.5%

Based on 755 completed trials

Clinical Trials (938)

Showing 20 of 20 trials
NCT03718780Not ApplicableCompletedPrimary

Assessment of Continuous Measurement of Transcutaneous CO2 for Evaluation of Alveolar Dead Space During Exercise

NCT06979518Phase 1CompletedPrimary

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GSK3862995B Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and European Ancestry

NCT06367686Completed

Detecting Systemic Carbon Dioxide Levels With a Novel Biosensor

NCT04669743Not ApplicableActive Not RecruitingPrimary

Innate Immunity in Ozone-induced Airway Inflammation in COPD

NCT04939454Not ApplicableCompletedPrimary

Involvement of Skeletal Muscle Fibrocytes in sarcOpenia in Patients With Chronic ObstRuctive Pulmonary Disease

NCT06154837Phase 1Active Not RecruitingPrimary

A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease

NCT06831994Not ApplicableActive Not Recruiting

Digital Implementation of the German S3 Clinical Practice Guideline for Multimorbidity

NCT06890208Completed

Chronical Illness-related Limitations of the Ability to Cope With Rising Temperatures, Third Wave

NCT02655302Not ApplicableTerminatedPrimary

Study of the Involvement of IL-17 / IL-22 Pathway in Bacterial Exacerbations of COPD

NCT06712563RecruitingPrimary

Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting

NCT06755008Not ApplicableRecruitingPrimary

Benefits of Epithelial Repair in COPD by Induced Pluripotent Stem Cells (iPS)

NCT05006560Not ApplicableCompletedPrimary

Internet-based Rehabilitation Aftercare Focusing on Physical Activity Promotion in Persons With COPD

NCT04027296CompletedPrimary

Development and Validation of the GLORI-COPD Score

NCT05704881RecruitingPrimary

Monitoring of the End-tidal Carbon Dioxide (EtCO2) as a Severity Criterion in COPD Exacerbations

NCT06961214Phase 3RecruitingPrimary

Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)

NCT05718102Not ApplicableRecruitingPrimary

Pragmatic Trial to Enhance Quality Safety, and Patient Experience in COPD

NCT02500693Not ApplicableCompleted

Circulating Tumor Cells in Lung Cancer Screening

NCT05592847Not ApplicableNot Yet Recruiting

A Study of the Effect of a Nurse Navigator Program on High Risk Patients

NCT06477367Not ApplicableCompletedPrimary

Changes in Dyspnea, Activity and Sleep in COPD by Video-Based Breathing Exercises

NCT05265299Phase 3RecruitingPrimary

Trial to Determine Effective Aspirin Dose in COPD

Scroll to load more

Research Network

Activity Timeline